Review: cellular senescence as a proposed link between chronic lung and metabolic disease
This review proposes cellular senescence as a common biological link between chronic pulmonary diseases and metabolic disorders such as obesity and type 2 diabetes, and discusses senescence-targeting therapies as a potential approach; clinical evidence is described as limited. [1]
Automatic summary · not editorially reviewed
The key findings
The review states that senescent cells accumulate progressively in tissues with aging and that their persistence contributes to tissue dysfunction via inflammatory and profibrotic mediators. [1]
Obesity and type 2 diabetes are described as worsening the development and progression of chronic pulmonary diseases. [1]
The review states that clinical evidence for senescence-targeting approaches remains limited. [1]
The source at a glance
- Study type / format
- Review (abstract only)
- Population / context
- Patients with chronic pulmonary diseases and metabolic disorders such as obesity and type 2 diabetes, discussed in a review.
- Summary based on
- Study abstract
- Original publication
- July 17, 2026
Senescent cells and age-related lung disease
The review states that aging is the primary risk factor for most chronic diseases and that senescent cells accumulate progressively in tissues. Cellular senescence initially limits proliferation of damaged cells, but its persistence is described as contributing to tissue dysfunction through inflammatory and profibrotic mediators. Chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis are said to increase markedly with age and are increasingly regarded as manifestations of accelerated lung aging.
Supporting source [1]
Proposed cycle linking metabolic and pulmonary disease
According to the review, obesity and type 2 diabetes are characterized by chronic metabolic stress, mitochondrial dysfunction, systemic inflammation and enhanced accumulation of senescent cells, and they are said to worsen the development and progression of chronic pulmonary diseases. Persistent inflammatory and profibrotic signaling from senescent cells is proposed to create a self-perpetuating cycle of chronic inflammation, extracellular matrix remodeling, fibrosis, endothelial dysfunction and impaired tissue repair, driving deterioration of both metabolic and pulmonary function.
Supporting source [1]
Senotherapies discussed, with limited clinical evidence
The review reports growing interest in strategies that reduce the burden of senescent cells or attenuate their effects. It lists novel senotherapies specifically targeting cellular senescence and established metabolic-disease therapies recently shown to have senescence-modulating effects. The review states that clinical evidence remains limited and presents targeting senescence as a potential opportunity to address aging biology rather than individual disease manifestations.
Supporting source [1]
How to interpret this
This is an abstract of a review; the full text was not reviewed. The proposed mechanistic links and therapeutic potential are described as emerging, and clinical evidence is stated to be limited. No human trial results, effect sizes or safety data are reported in the abstract.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Rennerova M, Zaloudikova M, Haluzik M, Stemberkova Hubackova S. · europepmc.org · July 17, 2026